FOR IMMEDIATE RELEASE
- New program addresses complementary and adjunctive technologies increasingly used in longevity and regenerative medicine practices
- Curriculum spans therapeutic plasma exchange, peptide medicine, IV therapy, and additional physician-directed technologies
- Certification helps physicians understand how multiple technologies fit within a comprehensive medical practice
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a new educational program focused on complementary and adjunctive technologies increasingly incorporated into longevity and regenerative medicine practices.
Curriculum areas include therapeutic plasma exchange (TPE), EBOO/EVO, peptide medicine, IV therapy, longevity medicine, artificial intelligence, PEMF, photobiomodulation/red-light technologies, hyperbaric medicine, and other physician-directed complementary technologies.
ISSCA said the program is designed to help physicians understand how multiple adjunctive technologies may fit within a comprehensive medical practice, rather than certifying any single modality in isolation.
“Physicians aren’t choosing between one technology and another anymore — they’re building comprehensive practices,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This certification is designed around that reality.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
